Clovis boasts promising ovarian cancer responses for AstraZeneca rival rucaparib

John Carroll

Over the weekend, Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant head-on with two key franchise showdowns. The Boulder, CO-based biotech posted positive data from a mid-stage study of its drug at ASCO, while adding new–though less impressive–data to back up its lead drug for non-small cell lung cancer.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS